Cognitive health assessments and lab tests designed to enhance the Alzheimer’s disease and dementia care pathway
Alzheimer’s disease is the most common cause of dementia, affecting over 6M people in the US.1 Diagnosis and care for patients with cognitive impairment is rapidly evolving, making assessing Alzheimer’s disease pathophysiology, as well as other dementias, key to timely intervention.
Improvement of patient outcomes and care pathways drives our commitment to offer one of the industry’s most comprehensive portfolios of lab tests for Alzheimer’s disease and dementia to help assess potential risk.
Quest AD-Detect® is a portfolio of blood-based risk assessment offerings that can help provide better understanding of a patient’s potential risk for dementia or Alzheimer’s disease. For patients who may want a less invasive option, a simple blood test can be the first step in taking action and help to determine if more comprehensive testing is needed.
Quest AD-Detect® Beta-Amyloid 42/40 Ratio
This test assesses beta-amyloid 42/40 (Aβ42/40) ratio via plasma. This ratio measures levels of 2 beta-amyloid peptides, where certain ratio results may suggest a risk of developing Alzheimer’s disease.2 Blood-based amyloid testing provides an accessible, affordable tool as part of Alzheimer’s disease risk assessment and ongoing monitoring, aiding in evaluation of further comprehensive testing needs.
Quest AD-Detect® Apolipoprotein (ApoE) Isoform
It’s critical to understand ApoE status for patients considering amyloid-modifying therapies. This test can provide insights on the presence of ApoE isoforms, a well-known biomarker associated with risk of developing Alzheimer’s disease.2 Insights into a patient’s ApoE status can help assess the risk of amyloid related imaging abnormalities (ARIA) in patients considering amyloid-modifying therapeutics. Quest (data on file) and others3,4 have shown that the results of phenotyping are 100% concordant with ApoE genotyping results.
Quest AD-Detect® p-tau181
This test is used to detect phosphorylated tau (p-tau181) proteins, one of the hallmark biomarkers involved in the diagnosis and staging of Alzheimer’s disease. P-tau181 concentrations increase over time within plasma as Alzheimer’s disease progresses.5,6 Routine monitoring of p-tau181 levels via plasma is ideal to support care pathways as it is less invasive, less expensive, and more practical than other methods. Combined plasma p-tau and Aβ42/40 biomarker testing has been shown to help identify patients at risk of experiencing faster cognitive decline7 and which patients can benefit from further diagnostic testing.
This test leverages our lab services and artificial intelligence (AI) technology from uMETHOD Health to deliver personalized treatment recommendations that address key contributors to memory loss, dementia, and mild cognitive impairment. RestoreU™ dementia risk assessment can help generate personalized care plans with evidence-based, actionable treatment recommendations. Read our press release about the RestoreU service.
This test measures beta-amyloid 40 (Aβ40) as well as Aβ42 in CSF, rather than Aβ42 alone. Using the ratio of Aβ42/40 improves sensitivity and specificity for Alzheimer’s patients.
This test combines ApoE results with Aβ42/40 ratio into an algorithm to assess Alzheimer’s disease risk, and can help assess the risk of amyloid related imaging abnormalities (ARIA) in patients considering amyloid-modifying therapeutics.
This test combines 3 biomarkers, phospho-tau, total tau, and Aβ42, to help you provide clinically relevant information regarding Alzheimer’s disease staging that may help guide patient management.
This test can provide insights on a patient’s ApoE status, a key biomarker associated with an increased risk of developing Alzheimer’s disease.8
Sign up to receive updates on Alzheimer’s disease and dementia blood tests.
References
1. CDC. Accelerating risk reduction and promoting brain health. Updated July 29, 2019. Accessed May 18, 2023. https://www.cdc.gov/aging/healthybrain/issuemaps/risk-reduction.html
2. Nakamura A, Kaneko N, Villemagne V, et al. High performance plasma amyloid-B biomarkers for Alzheimer’s disease. Nature. 2018;554(7691):249-254. doi:10.1038/nature25456
3. Nishimura M, Satoh M, Nishimura S, et al. Human apolipoprotein E resequencing by proteomic analysis and its application to serotyping. PLoS ONE. 2014;9(1):e85356. doi:10.1371/journal.pone.0085356
4. Kirmess KM, Meyer MR, Holubasch MS, et al. The PrecivityAD™ test: accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta. 2021;519:267-275. doi:10.1016/j.cca.2021.05.011
5. Lantero Rodriguez J, Karikari TK, Suárez-Calvet M, et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to postmortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140(3):267-278. doi:10.1007/s00401-020-02195-x
6. Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer’s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021;17(8):1353-1364. doi:10.1002/alz.12301
7. Meyer PF, Ashton NJ, Karikari TK, et al. Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults. Ann Neurol. 2022;91(4):548-560. doi:10.1002/ana.26308
8. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron. 2009;63(3):287-303. doi:10.1016/j.neuron.2009.06.026
Join our email community
Get the very latest news and information from Quest Diagnostics Neurology.
About our tests links
About our tests
-
Allergy & asthma -
Arthritis & rheumatoid arthritis -
Autoimmune diseases -
Bleeding & thrombosis -
Cancer -
Cardiometabolic disease -
Cardiovascular disease -
Chronic kidney disease -
Clinical drug monitoring -
Diabetes & prediabetes -
Endocrine disorders -
Gastrointestinal & digestive diseases -
Genetics -
Infectious diseases -
Micronutrients -
Neurology -
Nonalcoholic fatty liver disease -
Quest Advanced™ Specialized Transplant Services -
Women's health -
liver-diseases
- Site map
- Privacy Notices
- Terms
- Contact us
- Language assistance / non-discrimination
- Asistencia de idiomas / Aviso de no discriminación
- 語言協助 / 不歧視通知
- Accessibility
- Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.